依据新WHO分类的日本系统性慢性活动性EBV感染全国调查
本研究依据2017年WHO分类,对日本2003年1月至2016年3月新诊断的系统性慢性活动性EBV感染(sCAEBV)患者进行2016至2018年全国调查,评估100例患者特征及化疗效果。儿童起病组预后优于青少年/成人及老年起病组,化疗完全缓解率低,病毒学完全缓解未观察到,化疗后联合或单独异基因造血干细胞移植的3年总生存率分别为65%和82%。
要点
- 儿童起病组(<9岁)78%为男性,老年起病组(>45岁)85%为女性。
- 化疗完全缓解率:环孢素A+类固醇+依托泊苷(冷却疗法)17%,CHOP方案13%。
- 仅化疗、化疗后allo-HSCT、仅allo-HSCT的3年总生存率分别为0%、65%、82%。
核心结论
- 儿童起病与老年起病sCAEBV特征不同,可能为不同疾病。
- 化疗目前不足以消除疾病活动性及清除感染细胞,急需开发有效治疗。
研究设计与样本
- 日本全国性调查,纳入2003年1月至2016年3月新诊断的sCAEBV患者,调查时间为2016年至2018年,共评估100例。
主要发现
- 患者年龄1至78岁(中位21岁),男性53例,女性47例。
- 活动性疾病患者未观察到自发缓解。
- 儿童起病组(<9岁)78%为男性,老年起病组(>45岁)85%为女性。
- 儿童起病组预后优于青少年/成人起病组和老年起病组。
- 主要化疗方案:冷却疗法(环孢素A+类固醇+依托泊苷)52例,CHOP方案45例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic chronic active Epstein-Barr virus infection (sCAEBV) was defined as a T- or NK-cell neoplasm in the 2017 World Health Organization (WHO) classification. To clarify the clinical features of sCAEBV under this classification and review the effects of chemotherapy, we performed a nationwide survey in Japan from 2016 through 2018 of patients with sCAEBV newly diagnosed from January 2003 through March 2016. One hundred cases were evaluated. The patients were aged 1 to 78 years (median, 21) and included 53 males and 47 females. Spontaneous regression was not observed in patients with active disease. In the childhood-onset group (age, <9 years), 78% of the patients were male. In contrast, 85% of the patients in the elderly-onset group (age, >45 years) were female. The prognosis of the childhood-onset group was better than those of the adolescent/adult- and elderly-onset groups. The main chemotherapies used were a combination of cyclosporine A, steroids, and etoposide (cooling therapy) in 52 cases and cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) in 45 cases. The rate of complete response (CR), defined as complete resolution of disease activity, was 17% for cooling therapy and 13% for CHOP. Virological CR was not observed. The 3-year overall survival rates in patients treated with chemotherapy only (n = 20), chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT; n = 47), and allo-HSCT only (n = 12) were 0%, 65%, and 82%, respectively. Distinct characteristics were observed between childhood- and elderly-onset sCAEBV, and they appeared to be different disorders. Chemotherapy is currently insufficient to resolve disease activity and eradicate infected cells. The development of an effective treatment is urgently needed.
引用
- Yonese I, Sakashita C, Imadome KI, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020. PMID: 32598475. doi:10.1182/bloodadvances.2020001451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。